among
close
relat
orbivirus
reovirida
famili
bluetongu
viru
btv
epizoot
hemorrhag
diseas
viru
ehdv
african
hors
sick
ah
viru
ahsv
ahsv
known
caus
sever
morbid
mortal
infect
anim
suscept
hors
ahsv
caus
differ
form
diseas
rang
mild
fever
acut
form
character
high
fever
depress
respiratori
symptom
sever
weight
loss
rough
hair
lethargi
apathi
mortal
reach
although
ah
endem
subsaharan
africa
occasion
outbreak
signific
social
econom
impact
report
north
africa
pakistan
india
spain
portug
three
orbivirus
transmit
midg
culicoid
speci
circul
throughout
europ
unit
state
thu
increas
geographi
potenti
risk
ahsv
outbreak
similar
risk
btv
ehdv
genom
sequenc
ahsv
suffici
diverg
genom
sequenc
btv
ehdv
unlik
btv
serotyp
serotyp
ahsv
ahsv
serotyp
distinguish
date
vaccin
polyval
liveattenu
vaccin
lav
ahsv
current
use
control
diseas
africa
howev
vaccin
consid
unsaf
due
advers
side
effect
often
caus
viremia
potenti
reassort
wildtyp
ahsv
strain
result
possibl
spread
viru
infect
therefor
ration
design
safe
ahsv
vaccin
candid
current
develop
market
yet
ahsv
nonenvelop
viru
contain
doublestrand
rna
dsrna
segment
outer
capsid
compos
two
major
structur
protein
serotypedetermin
protein
variabl
viral
protein
major
target
protect
immun
respons
core
particl
consist
two
concentr
layer
surfac
layer
inner
layer
enclos
genom
dsrna
segment
replicas
complex
three
enzym
comparison
sequenc
capsid
protein
btv
serotyp
ehdv
serotyp
reveal
close
structur
relationship
virus
inner
core
protein
conserv
wherea
outermost
protein
variabl
previou
structur
studi
btv
reveal
atomiclevel
detail
btv
particl
organ
expect
ahsv
architectur
structur
organ
similar
btv
howev
level
individu
protein
structur
top
domain
report
therefor
molecular
understand
structurefunct
relationship
ahsv
protein
avail
structurebas
ration
vaccin
design
ahsv
current
possibl
past
decad
revers
genet
rg
technolog
revolution
understand
btv
replic
pathogenesi
greatli
advanc
develop
vaccin
technolog
rg
technolog
ahsv
strain
demonstr
need
signific
improv
increas
effici
viru
recoveri
similar
rgbase
approach
develop
liveattenu
provid
promis
approach
vaccin
develop
rg
technolog
btv
defect
encod
complement
cell
line
made
possibl
rapid
gener
disabl
infecti
singl
cycl
disc
vaccin
strain
strategi
demonstr
effici
differ
serotyp
reassort
two
variabl
rna
segment
encod
outer
capsid
protein
remain
eight
rna
segment
includ
singlestrand
rna
ssrna
encod
defect
importantli
disc
virus
show
effici
replic
complement
cell
line
viru
product
mammalian
insect
cell
line
vaccin
cattl
sheep
disc
virus
either
singli
cocktail
follow
challeng
virul
btv
strain
show
neither
clinic
reaction
detect
viremia
base
highli
promis
disc
btv
vaccin
technolog
aim
improv
adapt
gener
ahsv
vaccin
strain
first
employ
rg
system
product
high
titer
virus
sole
complement
cell
line
achiev
defect
strain
util
strain
backbon
develop
defectiveviru
vaccin
specif
nine
serotyp
howev
spite
structur
similar
btv
ahsv
becam
clear
unlik
result
obtain
btv
serotyp
exchang
serotyp
respect
segment
gener
viabl
reassort
virus
indic
protein
highli
conserv
differ
serotyp
therefor
necessari
exchang
addit
segment
certain
serotyp
vaccin
strain
test
protect
efficaci
type
interferon
receptor
ifnar
knockout
mice
vaccin
mice
challeng
two
virul
strain
ahsv
complet
protect
homolog
infect
achiev
demonstr
suitabl
vaccin
strain
vaccin
candid
bsr
cell
subclon
cell
maintain
dulbecco
modifi
eagl
medium
dmem
sigma
supplement
fetal
bovin
serum
fb
invitrogen
stabl
cell
line
grown
fb
supplement
puromycin
sigma
equin
dermal
e
derm
cell
atcc
cultur
eagl
minimum
essenti
medium
mem
sigma
supplement
fb
nonessenti
amino
acid
mammalian
cell
line
cultur
humidifi
atmospher
insect
kc
cell
deriv
culicoid
midg
maintain
schneider
insect
medium
supplement
fb
ahsv
serotyp
kindli
suppli
zientara
ans
franc
ahsv
serotyp
passag
bsr
cell
titrat
use
subsequ
experi
challeng
strain
kindli
provid
manuel
universidad
complutens
de
madrid
spain
rg
system
code
region
correspond
segment
insert
pcagpm
vector
use
aflii
paci
restrict
site
correspond
express
plasmid
design
confirm
sequenc
plasmid
carri
ahsv
transcript
gener
use
sequenceindepend
clone
system
previous
describ
briefli
genom
dsrna
ligat
selfann
primer
revers
transcript
rt
pcr
amplif
adaptor
primer
cdna
amplifi
ahsv
segment
clone
vector
sequenc
mutant
contain
stop
codon
taa
tga
throughout
gene
creat
gene
assembl
introduct
mutat
posit
stop
codon
frameshift
stop
codon
stop
codon
stop
codon
sequenc
confirm
complement
cell
line
express
cell
line
gener
describ
previous
modif
briefli
bsr
cell
transfect
electropor
v
vector
electropor
suspens
cell
seed
onto
cultur
plate
coloni
select
presenc
puromycin
surviv
clone
test
immunoblot
analysi
use
polyclon
guinea
pig
antiserum
rais
crossreact
bestexpress
clone
use
recoveri
virus
promot
exact
end
contain
dna
use
templat
equimolar
proport
produc
mixtur
cap
rna
transcript
use
mmessag
mmachin
ultra
kit
ambion
accord
manufactur
instruct
recoveri
strain
rg
strain
bsr
cell
confluenc
plate
transfect
set
express
plasmid
carri
gene
differ
combin
ng
plasmid
per
well
h
posttransfect
hpt
cell
transfect
second
time
total
ng
cap
rna
transcript
assess
rna
infect
h
second
transfect
monolay
overlaid
lowtemperatur
agaros
catalog
number
sigma
dmem
contain
fb
incub
day
format
plaqu
altern
collect
recov
virus
transfect
medium
replac
dmem
contain
fb
incub
continu
day
appear
cytopath
effect
recoveri
cell
confluenc
plate
transfect
pcag
plasmid
carri
gene
ng
follow
second
transfect
hpt
total
ng
cap
rna
transcript
obtain
reassort
defahsv
sever
segment
use
replac
parent
defect
viru
plaqu
purifi
titrat
cell
assess
stabil
defect
viru
passag
least
time
cell
multipl
infect
moi
analysi
dsrna
profil
rtpcrsequenc
use
confirm
integr
introduc
ahsv
segment
growth
kinet
wt
ahsv
defect
virus
determin
bsr
kc
e
derm
cell
follow
infect
h
moi
respect
infect
inoculum
remov
cell
wash
twice
medium
supplement
fb
h
postinfect
hpi
supernat
harvest
titer
cell
determin
plaqu
assay
express
number
pfu
per
millilit
experi
perform
triplic
repeat
twice
three
strain
wt
use
experi
obtain
rg
exact
copi
rna
wt
obtain
second
bsr
cell
passag
origin
stock
ahsvkc
viru
passag
twice
kc
cell
moi
three
ahsv
stock
show
similar
result
data
shown
therefor
data
one
strain
present
thirti
mice
mous
genet
background
obtain
specificpathogenfre
breed
unit
friedrichloeffl
institut
germani
assign
group
male
femal
anim
distribut
equal
six
mice
immun
subcutan
twice
week
apart
pfu
also
challeng
rout
day
second
immun
tissu
cultur
infect
dose
either
ahsv
serotyp
group
ahsv
serotyp
group
twelv
mice
mock
vaccin
phosphatebuff
salin
pb
six
infect
six
infect
six
mice
kept
control
experiment
protocol
review
state
ethic
commiss
landesamt
landwirtschaft
lebensmittelsicherheit
und
fischerei
mecklenburgvorpommern
lallf
approv
compet
author
refer
number
lallf
mice
weigh
daili
day
vaccin
infect
examin
clinic
sign
includ
weight
loss
rough
hair
lethargi
apathi
neurolog
sign
ataxia
paresi
one
leg
paralysi
observ
report
previous
anim
show
sever
symptom
immedi
euthan
remain
infect
untreat
control
anim
euthan
week
challeng
blood
sampl
obtain
mice
day
infect
autopsi
blood
spleen
liver
brain
sampl
taken
organ
sampl
homogen
ml
serumfre
mem
rna
blood
tissu
homogen
extract
use
kingfish
flex
purif
system
thermo
scientif
braunschweig
germani
combin
magattract
viru
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
analyz
realtim
rtquantit
pcr
qpcr
assay
combin
intern
control
system
target
betaactin
housekeep
gene
effici
rg
system
offer
rapid
approach
manipul
viral
genom
allow
molecular
mechan
viral
gene
gene
product
understood
previous
publish
ahsv
rg
system
use
transfect
mixtur
two
differ
serotyp
name
six
plasmid
express
follow
rna
transcript
order
recov
viabl
viru
howev
combin
found
insuffici
molecular
manipul
due
low
effici
recoveri
viru
present
titer
less
pfuml
therefor
necessari
identifi
wellrepl
ahsv
serotyp
uniform
larg
plaqu
viru
recoveri
rg
system
nine
wt
ahsv
serotyp
test
bsr
cell
assess
viru
titer
plaqu
phenotyp
fig
three
distinct
group
ahsv
serotyp
observ
larg
defin
plaqu
phenotyp
high
titer
medium
plaqu
phenotyp
high
titer
smallundefin
plaqu
phenotyp
low
titer
four
wellrepl
ahsv
serotyp
analyz
genet
stabil
via
sequenc
sever
plaquepurifi
isol
three
show
high
genet
divers
avoid
complic
plaquepurifi
exhibit
larg
uniform
plaqu
phenotyp
high
titer
pfuml
consid
suitabl
use
rg
system
recoveri
full
copi
rna
segment
perform
sequenceindepend
method
describ
previous
segment
promoterderiv
plasmid
exact
end
gener
produc
cap
rna
transcript
proteincod
sequenc
form
primari
replicas
complex
use
gener
express
plasmid
control
pcag
promot
rg
system
test
sever
condit
mimic
preform
primari
replic
complex
transfect
express
plasmid
follow
transfect
exact
copi
rna
transcript
perform
combin
express
plasmid
express
found
suffici
gener
high
number
ahsv
plaqu
use
throughout
subsequ
experi
fig
isol
plaqu
amplifi
bsr
cell
viru
titer
high
pfuml
equival
wt
viru
plaqu
morpholog
genom
dsrna
profil
similar
wt
fig
data
demonstr
effici
rg
system
requir
primari
transfect
subcor
express
plasmid
follow
transfect
exact
copi
ssrna
transcript
effici
rg
system
suitabl
gener
target
highli
defect
ahsv
strain
facilit
function
structur
studi
without
requir
highcontain
environ
previous
shown
product
involv
ssrna
packag
helicas
activ
therefor
decid
develop
virus
requir
gener
cell
line
complement
abil
transcomplement
rg
system
relat
viru
btv
led
develop
mutant
virus
abl
replic
complement
cell
line
bsr
insect
kc
cell
therefor
creat
bsr
cell
line
express
cell
line
electropor
bsr
cell
follow
puromycin
select
select
clone
stabli
express
passag
low
dilut
fig
addit
also
encod
minor
nonstructur
protein
dispens
btv
replic
bsr
cell
construct
introduc
multipl
nucleotid
chang
instead
use
delet
report
btv
introduc
stop
codon
taa
tga
throughout
gene
disrupt
open
read
frame
orf
retain
length
rna
thu
minim
genet
pressur
defect
recoveri
replic
absenc
expect
compens
complement
cell
line
use
newli
develop
complement
cell
line
could
recov
transfect
express
plasmid
follow
transfect
cap
rna
transcript
replac
segment
second
transfect
agaroverlaid
monolay
use
assess
rna
infect
compar
wt
fig
recov
viru
plaqu
purifi
use
cell
line
amplifi
titer
pfuml
titrat
complement
cell
line
reach
plaqu
morpholog
fig
analysi
genom
dsrna
segment
show
expect
dsrna
profil
fig
confirm
ahsv
effici
complement
dispens
ahsv
replic
bsr
cell
abil
orbivirus
reassort
provid
possibl
coat
conserv
replicas
complex
inner
core
outer
capsid
therebi
result
serotypespecif
particl
particl
may
broad
applic
spectra
exampl
vaccin
candid
safe
platform
structur
molecular
studi
previous
demonstr
exchang
ahsv
lower
reassort
viru
titer
log
unit
result
impair
replic
andor
particl
instabl
therefor
aim
util
backbon
achiev
wellrepl
defect
strain
ahsv
serotyp
exchang
combin
differ
segment
initi
exact
copi
segment
serotyp
clone
sequenc
amino
acid
sequenc
analysi
major
structur
protein
nine
ahsv
serotyp
reveal
increas
degre
conserv
expect
order
least
conserv
ident
similar
follow
ident
similar
conserv
ident
similar
produc
rna
transcript
exact
copi
dna
clone
genom
segment
gener
describ
defectiveviru
recoveri
cell
transfect
complet
set
rna
replac
depend
serotyp
combin
use
replac
equival
segment
criteria
select
defect
virus
plaqu
size
clear
plaqu
day
incub
final
titer
plaquepurifi
virus
determin
use
cell
line
pfuml
requir
chosen
minim
possibl
pressur
avoid
recombin
instabl
modifi
dsrna
genom
expect
exchang
result
either
viru
recoveri
poor
recoveri
titer
rang
observ
consist
previous
publish
ahsv
reassort
base
exchang
develop
stabl
hightit
defect
virus
differ
serotyp
replac
two
outer
capsid
protein
suffici
serotyp
wellrepl
could
achiev
reassort
segment
encod
outer
shell
protein
achiev
addit
homolog
encod
scaffold
protein
deposit
also
exchang
tabl
three
addit
serotyp
creat
reassort
segment
result
set
creat
complet
replac
major
structur
protein
shell
gener
wellrepl
cell
reassort
five
segment
replac
achiev
high
titer
complement
cell
line
tabl
case
requir
combin
segment
replac
defect
virus
poorli
recov
virus
exhibit
small
plaqu
phenotyp
low
titer
rang
pfuml
therefor
exclud
subsequ
studi
schemat
represent
select
defect
virus
summar
fig
b
defect
virus
passag
time
moi
complement
cell
line
confirm
step
none
test
stock
abl
replic
wildtyp
bsr
cell
assess
stabil
integr
reassortantdefect
virus
dsrna
extract
stock
initi
viru
recoveri
final
fifth
passag
dsrna
sampl
exhibit
correct
mobil
fig
rtpcr
sequenc
also
valid
authent
rna
segment
defectiveviru
strain
determin
growth
kinet
defect
virus
complement
cell
infect
viru
low
moi
viru
titer
determin
hpi
similar
wt
defect
virus
capabl
replic
complement
cell
reach
titer
rang
pfuml
form
plaqu
day
postinfect
fig
defahsv
variant
propag
five
time
low
moi
complement
cell
cell
aliquot
passag
correspond
particl
test
wt
bsr
cell
ensur
defect
properti
expect
viru
growth
confirm
safeti
defahsv
variant
confirm
parent
eight
reassortantdefect
virus
incap
growth
normal
cell
growth
kinet
defect
viru
evalu
infect
three
differ
normal
cell
line
bsr
culicoid
kc
cell
e
derm
cell
high
moi
measur
viru
titer
hpi
result
demonstr
defect
virus
abl
grow
three
cell
line
fig
ensur
delay
replic
infect
cell
incub
addit
day
howev
sign
infect
detect
data
shown
result
taken
togeth
conclud
nine
defect
virus
grew
high
titer
pfuml
complement
cell
line
tabl
produc
viabl
virion
normal
bsr
kc
e
derm
cell
consid
standard
vaccin
dose
per
hors
viru
particl
quadrival
vaccin
maximum
inject
volum
exceed
ml
sinc
cell
infect
defahsv
serotyp
provid
least
dose
suggest
product
appropri
clinic
applic
mass
product
result
demonstr
great
potenti
defect
virus
use
safe
ahsv
vaccin
candid
proof
principl
reassort
assess
protect
efficaci
ahsv
infect
anim
model
sinc
adult
interferonknockout
mice
shown
suscept
ahsv
prove
appropri
model
test
ahsv
vaccin
efficaci
hors
two
group
mice
immun
twice
pfu
either
advers
side
effect
observ
vaccin
bodi
weight
immun
control
anim
show
signific
differ
maximum
variat
observ
group
week
second
immun
vaccin
control
anim
challeng
subcutan
virul
protect
indic
includ
bodi
weight
measur
surviv
time
blood
tissu
ahsvspecif
rna
level
group
control
mice
vaccin
challeng
start
lose
weight
day
postchalleng
onward
four
anim
euthan
day
infect
sever
weight
loss
rough
hair
apathet
behavior
two
remain
mice
euthan
day
nonvaccin
mous
group
infect
repres
less
virul
serotyp
show
clinic
sign
also
group
mice
vaccin
either
show
clinic
sign
fig
level
viremia
determin
analysi
amount
ahsvspecif
rna
present
blood
measur
mice
day
infect
ahsvspecif
rna
detect
mockinfect
mice
mice
infect
significantli
higher
ahsv
rna
level
mice
infect
fig
data
correl
mous
surviv
time
fig
suggest
repres
less
virul
serotyp
immun
anim
group
level
viremia
significantli
reduc
fig
analysi
ahsvspecif
rna
combin
intern
control
system
target
betaactin
housekeep
gene
present
collect
blood
sampl
threshold
cycl
ct
valu
spleen
liver
brain
tissu
sampl
taken
rna
extract
rna
quantifi
describ
materi
method
consist
previou
data
fig
b
high
load
ahsv
rna
measur
organ
nonvaccin
mice
infect
wherea
analyz
organ
group
demonstr
low
ahsv
rna
level
ahsv
rna
expect
vaccin
prior
homolog
ahsv
challeng
led
signific
reduct
ahsv
rna
level
mous
organ
fig
nonimmun
mice
infect
show
detect
level
ahsvspecif
rna
mice
mortal
weight
loss
contrast
find
mice
reason
ahsvspecif
rna
level
chosen
main
protect
indic
analysi
potenc
vaccin
candid
african
hors
sick
remain
actual
threat
speci
equida
africa
countri
surround
mediterranean
although
liveattenu
polyval
vaccin
protect
almost
ahsv
serotyp
except
serotyp
commerci
avail
vaccin
strain
high
risk
reassort
field
isol
result
introduct
new
viru
serotyp
countri
ahsv
endem
therefor
last
decad
variou
attempt
made
develop
safe
efficaci
ahsv
vaccin
howev
date
none
develop
commerci
product
success
vaccin
prepar
addit
safeti
efficaci
essenti
criteria
also
met
includ
technic
simplic
reproduc
eas
scale
product
downstream
process
manufactur
vaccin
importantli
costeffect
vaccin
manufactur
particularli
anim
vaccin
moreov
vaccin
could
allow
differenti
infect
vaccin
anim
diva
also
highli
desir
although
subunit
vaccin
base
purifi
protein
compliant
need
diva
safe
gener
provid
suffici
longlast
protect
product
costli
orbiviruslik
particl
safe
provid
suffici
protect
requir
complex
prepar
method
suffer
low
yield
problem
reproduc
although
attenu
virusbas
chimera
creat
exchang
outer
capsid
protein
alon
combin
good
immunolog
potenti
far
demonstr
signific
variabl
viru
titer
often
low
pfuml
preclud
develop
costeffici
product
therefor
studi
priorit
viru
product
paramet
overcom
defici
gener
ahsv
vaccin
candid
base
previou
research
orbivirus
consid
creation
replicationdefici
viru
particl
enclos
effici
replicas
backbon
viru
coat
immunogen
capsid
protein
ahsv
serotyp
promis
strategi
purpos
effici
replic
plaquepurifi
variant
first
select
provid
highest
titer
defin
larg
plaqu
phenotyp
second
genom
segment
variant
subclon
sequenc
effici
rg
system
along
optim
viru
recoveri
paramet
establish
found
doubletransfect
approach
cell
first
transfect
dna
express
vector
provid
highlevel
express
primari
replic
complex
compon
protein
follow
transfect
vitrocotranscrib
rna
repres
exact
copi
viru
segment
effici
method
ahsv
recoveri
similar
previous
report
btv
creat
replicationdefect
viru
target
disrupt
orf
essenti
replic
enzym
well
overlap
orf
less
wellstudi
protein
code
region
segment
introduc
multipl
stop
codon
notabl
mutat
introduc
segment
suffici
allow
differenti
infect
vaccin
anim
quantit
rtpcr
howev
need
confirm
futur
experi
support
replic
defect
viru
necessari
establish
complement
bsr
cell
line
express
function
cell
highli
effici
support
propag
defect
therefor
consid
suitabl
backbon
gener
defect
viru
strain
remain
eight
serotyp
exchang
rna
segment
encod
serotypedetermin
capsid
protein
serotyp
similar
strategi
creat
replicationdefici
viru
strain
previous
report
btv
adenoviru
herp
simplex
viru
virus
review
refer
defect
virus
advantag
vaccin
initi
infect
site
mimic
replic
viru
thu
provid
strong
specif
immun
respons
sinc
viral
infect
major
neutral
immun
respons
base
protein
would
logic
assum
exchang
correspond
segment
would
suffici
howev
sinc
product
vaccin
strain
also
critic
sought
optim
condit
gener
vaccin
strain
found
eight
ahsv
serotyp
rescu
correspond
virus
use
establish
rg
system
possibl
serotyp
titer
viral
stock
unaccept
lower
pfuml
parent
viru
low
titer
rescu
viru
would
imped
develop
costeffici
vaccin
candid
also
indic
problem
associ
viru
assembl
dissemin
possibl
genet
stabil
expect
swap
larg
variabl
rna
segment
segment
alter
serotyp
viru
particl
may
number
consequ
orbiviru
particl
made
three
concentr
layer
protein
wherea
make
contact
outer
capsid
protein
inner
capsid
protein
therefor
amino
acid
chang
replac
may
disturb
interact
capsid
protein
thu
influenc
stabil
assembl
virion
addit
orbivir
rna
segment
need
interact
also
may
interact
packag
protein
assembl
integr
nativ
crucial
therefor
variat
nucleotid
sequenc
level
may
also
result
reduc
effici
core
assembl
heterolog
viru
end
current
knowledg
nucleotidelevel
requir
rna
packag
atomiclevel
structur
detail
ahsv
virion
organ
clearli
lag
behind
preclud
ration
design
optim
reassort
viru
particl
therefor
use
semir
approach
replac
along
also
highli
variabl
among
differ
ahsv
serotyp
assum
advantag
replac
rna
report
especi
import
rna
packag
wherea
orf
encod
protein
implic
viru
bud
process
test
variou
combin
select
viru
variant
effici
replic
titer
equival
wt
viru
interestingli
number
segment
need
exchang
backbon
viru
differ
differ
serotyp
extrem
case
requir
exchang
five
segment
includ
data
agreement
previous
publish
report
btv
interact
shown
import
effici
viru
egress
howev
possibl
rnarna
interact
involv
effici
reassort
ahsv
serotyp
also
consid
sinc
adult
mice
infect
ahsv
show
clinic
diseas
pathogenesi
success
use
ahsv
vaccin
efficaci
studi
vaccin
also
confer
protect
hors
mice
appropri
model
evalu
protect
efficaci
defect
virus
two
differ
defect
virus
includ
one
reassortantdefect
viru
assess
vaccin
group
mice
demonstr
significantli
decreas
level
viremia
contrast
control
nonvaccin
group
show
high
level
viremia
andor
clinic
sign
although
data
highli
encourag
vaccinationchalleng
experi
differ
combin
serotyp
need
assess
use
mice
also
hors
liveattenu
ahsv
vaccin
extens
use
south
africa
sever
decad
recent
one
lav
strain
delet
employ
potenti
vaccin
develop
platform
howev
recent
report
anoth
rna
viru
demonstr
revers
virul
attenu
sever
acut
respiratori
syndrom
coronaviru
lack
e
protein
propag
mice
therefor
vitro
complement
miss
protein
would
repres
safer
ahsv
vaccin
platform
minim
genet
pressur
toward
revers
virul
notabl
studi
avoid
delet
gene
disrupt
orf
ahsv
code
introduc
multipl
stop
codon
multipl
passag
vaccin
strain
complement
cell
line
reveal
chang
mutat
strongli
suggest
mutat
orf
unlik
revert
also
result
demonstr
nine
defect
ahsv
abl
replic
complement
cell
line
titer
similar
wt
ahsv
serotyp
importantli
defect
virus
unabl
propag
normal
cell
whether
mammalian
insect
origin
unlik
liveattenu
vaccin
strain
defahsv
vaccin
candid
replic
defici
normal
cell
activ
limit
primari
express
viral
protein
make
risk
recombin
circul
field
strain
minim
result
vaccin
provid
safer
option
hors
current
liveattenu
viru
vaccin
equival
improv
protect
effici
